OTCMKTS:GBLX GB Sciences (GBLX) Stock Price, News & Analysis $0.0003 0.00 (0.00%) As of 07/27/2026 03:50 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartSEC FilingsBuy This Stock About GB Sciences Stock (OTCMKTS:GBLX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get GB Sciences alerts:Sign Up Key Stats Today's Range$0.0003▼$0.000450-Day Range N/A52-Week Range$0.0001▼$0.0080Volume17,153 shsAverage Volume34,344 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview GB Sciences, Inc. is a biotechnology company focused on the research, development and commercialization of cannabinoid-based medicines. Leveraging both botanical and synthetic approaches, the company aims to create novel therapies targeting oncology, neurology and inflammatory diseases. Through its proprietary drug discovery platform, GB Sciences seeks to identify and advance lead compounds that harness the therapeutic potential of cannabinoids while ensuring high standards of quality and safety. The company operates a cGMP-compliant research and manufacturing facility in Irvine, California, and maintains partnerships to support cultivation and extraction activities in select geographies. GB Sciences has secured licenses for cannabis cultivation and product manufacturing in Panama, positioning the company to serve markets across North and Central America. Its product pipeline includes preclinical and early-stage clinical candidates, as well as formulations designed for future human trials in key therapeutic areas. GB Sciences’ leadership team combines expertise in pharmaceutical development, botanical extraction and regulatory compliance. The company is led by President and Chief Executive Officer Dr. Federico Narváez, MD, whose background spans clinical research and drug development. Supported by scientific and operational executives, GB Sciences continues to pursue strategic collaborations and patent-protected innovations aimed at translating cannabinoid science into meaningful medical treatments.AI Generated. May Contain Errors. Read More GB Sciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks2nd Percentile Overall ScoreGBLX MarketRank™: GB Sciences scored higher than 2% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for GB Sciences. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of GB Sciences is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of GB Sciences is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares ShortedShort Interest Ratio / Days to CoverGB Sciences has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in GB Sciences has recently increased by 100.00%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldGB Sciences does not currently pay a dividend.Dividend GrowthGB Sciences does not have a long track record of dividend growth. News and Social Media1.3 / 5News SentimentN/A News SentimentGB Sciences has a news sentiment score of -1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.91 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for GB Sciences this week, compared to 0 articles on an average week.MarketBeat Follows1 people have added GB Sciences to their MarketBeat watchlist in the last 30 days. Company Ownership0.2 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, GB Sciences insiders have not sold or bought any company stock.Percentage Held by Institutions13.56% of the stock of GB Sciences is held by institutions.Read more about GB Sciences' insider trading history. Receive GBLX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for GB Sciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. GBLX Stock News HeadlinesGB Sciences Inc.March 27, 2026 | barrons.comGB Sciences Delays Filing of Quarterly ReportNovember 19, 2025 | tipranks.comALT SL: New Patent Reveals Elon Musk’s Next Breakthrough: M.A.G.I.Jeff Brown and Marc Chaikin - two investors who spotted Nvidia a decade ago - are now pointing to Elon Musk's latest AI patent as the catalyst behind their next major call. They say a market pattern with a 100% historical track record is converging with this new breakthrough by end of month. The last time conditions aligned like this, investors had the chance to turn $10,000 into as much as $350,000 in roughly 12 months. Brown and Chaikin have released the full details for investors who want to get ahead of it.July 28 at 1:00 AM | Brownstone Research (Ad)GB Sciences Delays Filing of Quarterly ReportOctober 17, 2025 | tipranks.comGB Sciences, Inc. (GBLX) - Yahoo FinanceJuly 9, 2025 | finance.yahoo.comGB Sciences Reports Delay in Quarterly FilingFebruary 12, 2025 | tipranks.comGB Sciences, Inc. (GBLX) stock forecast and price targetJanuary 25, 2025 | finance.yahoo.comGB Sciences Inc (GBLX)August 23, 2024 | investing.comSee More Headlines GBLX Stock Analysis - Frequently Asked Questions How have GBLX shares performed this year? GB Sciences' stock was trading at $0.0005 at the beginning of the year. Since then, GBLX shares have decreased by 40.0% and is now trading at $0.0003. How were GB Sciences' earnings last quarter? GB Sciences, Inc. (OTCMKTS:GBLX) issued its quarterly earnings results on Monday, November, 14th. The company reported ($0.04) earnings per share for the quarter. How do I buy shares of GB Sciences? Shares of GBLX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of GB Sciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that GB Sciences investors own include Canopy Growth (CGC), 22nd Century Group (XXII), NVIDIA (NVDA), Unrivaled Brands (TRTC), TREES (CANN), Aurora Cannabis (ACB) and Meta Platforms (META). Company Calendar Last Earnings11/14/2016Today7/28/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Biotechnology Sub-IndustryCannabis Current SymbolOTCMKTS:GBLX CIK1165320 Webgbsciences.com Phone(866) 721-0297FaxN/AEmployees3Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free Report This page (OTCMKTS:GBLX) was last updated on 7/28/2026 by MarketBeat.com Staff. From Our PartnersNevada gold explorer near Kinross district draws attentionGold has surged past $5,300 per ounce, with Goldman Sachs and JPMorgan forecasting $6,000+ by end of 2026. Cen...Wall Street Logic | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | SponsoredHow the JPMorgan $8,000 Gold Call Exposed the Biggest Mistake in Most Retirement AccountsJPMorgan has raised its 2026 gold forecast to $6,300, with a credible path to $8,000, and now calls gold a cor...Golden Crest Metals | SponsoredA 50-year dollar arrangement just ended - what it means for youIn 1974, Henry Kissinger helped create the U.S.-Saudi Arabia Joint Commission on Economic Cooperation - a litt...Golden Portfolio | SponsoredSpaceX pays a 10X launch penaltySpaceX burns roughly $200,000 in fuel per Falcon 9 launch - about $20 million across 100 missions. One unde...Freedom Financial | Sponsored60 years. Zero competitors.One company has spent 60 years developing an energy source the International Energy Agency estimates at 140 ti...Behind the Markets | SponsoredBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...Chaikin Analytics | SponsoredWhat Elon told his top shareholders in TexasLate last year, Elon Musk gathered top shareholders at Tesla's Texas Gigafactory to unveil a plan to double Am...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GB Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share GB Sciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.